On August 28, 2025, Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) announced the appointment of Abhinav “Abi” Jain as an independent member of its Board of Directors. Jain will serve as a Class III director with a term ending at the Company’s 2026 Annual Meeting of Stockholders. Additionally, he will join the Compensation Committee and Nominating and Corporate Governance Committee. This decision comes after a cooperation agreement was reached with Nantahala Capital Management, LLC, which holds around 38% of Eagle's outstanding shares. Per the agreement, Eagle will appoint a second independent director to the Board by May 15, 2026.